HUTCHMED (China) Ltd — FY2018 Form 20-F
Reporting period: Year ended December 31, 2018; this is an annual report, not a standalone Q4 filing. Consolidated financial statements are prepared under U.S. GAAP and reported in U.S. dollars. Amounts below are in millions unless stated otherwise.
Business context and financial performance
HUTCHMED combines an Innovation Platform developing oncology and immunology drug candidates with a China-focused Commercial Platform distributing prescription and consumer health products. In September 2018, fruquintinib (Elunate) was approved in China for third-line metastatic colorectal cancer; commercial sales began in November. The company reported eight clinical-stage candidates.
| Metric | FY2018 | FY2017 |
|---|---|---|
| Revenue | $214.1 | $241.2 |
| Operating expenses | $306.8 | $294.6 |
| Loss from operations | $(92.6) | $(53.4) |
| Net loss attributable to the company | $(74.8) | $(26.7) |
| Basic and diluted loss per share | $(1.13) | $(0.43) |
| Net cash used in operating activities | $(32.8) | $(8.9) |
| Cash and cash equivalents | $86.0 | $85.3 |
| Short-term investments | $214.9 | $273.0 |
| Bank borrowings | $26.7 | $30.0 |
Research and development expense rose 51% to $114.2 million, equal to 53.3% of revenue, as clinical programs and staffing expanded. Selling expense fell to $17.7 million; administrative expense rose 29% to $30.9 million. The filing does not present a single consolidated gross-margin measure that is directly comparable across the reported business mix.
Liquidity, cash flow and debt
- Current assets were $370.5 million against current liabilities of $85.5 million; cash, short-term investments and unused bank facilities totaled approximately $420.3 million at year-end. The company reported $119.4 million of unused facilities.
- Operating cash outflow increased to $32.8 million. Investing activities generated $43.8 million, mainly reflecting withdrawals of short-term deposits; financing activities used $8.2 million. Cash and cash equivalents increased by $0.8 million before exchange-rate effects.
- Year-end bank debt was a $26.7 million term loan due in November 2020. Management said available resources and expected operating cash flows would fund planned operations and commitments for at least 12 months, while noting estimates depend on assumptions and further financing might be needed for planned development.
- No dividends were proposed or paid. The company said it did not plan to pay dividends in the foreseeable future.
Changes versus FY2017 and unusual items
- Revenue declined 11.2%. Commercial Platform revenue fell 15.8% to $172.9 million, mainly because China’s two-invoice distribution reform shifted some transactions from gross product sales to net service-fee reporting. Management expected further revenue effects in 2019, while saying the change had no material impact on profitability.
- Innovation Platform revenue rose 14.5% to $41.2 million, including a $13.5 million milestone following fruquintinib approval and $3.6 million from Elunate sales and royalties.
- Equity-method earnings from investees fell to $19.3 million from $33.7 million. Nutrition Science Partners recorded a full $30.0 million impairment of its intangible asset; HUTCHMED’s share of the resulting loss was $15.0 million. The joint venture was exploring a buyer or collaboration partner for the program.
- Commercial Platform equity earnings were $38.3 million, broadly level with $38.2 million in 2017. Shanghai Hutchison Pharmaceuticals’ profit rose to $59.8 million, while Hutchison Baiyunshan’s attributable profit fell to $16.9 million from $20.8 million.
- HUTCHMED adopted ASC 606 in 2018, recording a $1.1 million opening deferred-revenue adjustment. The filing’s comparison indicates 2018 revenue was $0.7 million lower than under the former accounting standard.
Outlook, commentary and principal risks
Management expected R&D spending to increase as trials advance and planned to expand clinical operations in the United States and Europe. Priorities included global development of savolitinib, fruquintinib and surufatinib, and advancing HMPL-523 and HMPL-689. The company outlined plans for a U.S./Europe fruquintinib registration study and anticipated 2019 interim analyses in China for surufatinib Phase III studies; these are plans, not guaranteed outcomes.
- Elunate’s commercial opportunity remained uncertain: it was not on China’s national reimbursement catalogue at filing, although it had entered certain city-level reimbursement lists. Uptake, pricing, reimbursement and Lilly’s commercialization execution are key uncertainties.
- Fruquintinib’s FALUCA Phase III lung-cancer trial did not meet its primary overall-survival endpoint, though secondary endpoints improved versus placebo. Full analysis was expected to be presented in 2019.
- Pipeline development carries clinical, regulatory, enrollment, safety and manufacturing risks. The company also cited reliance on collaborators, CROs and third-party suppliers, including a single commercial active-ingredient supplier for fruquintinib.
- Other material exposures include dependence on joint-venture earnings and dividends, China’s distribution and pricing reforms, foreign-exchange and capital controls, competition, and possible need for additional funding. The company had no material pending legal proceedings reported.
- The company reported effective disclosure controls and internal control over financial reporting as of year-end; the auditor issued unqualified opinions on the financial statements and internal controls. The filing also notes that PCAOB inspection access to auditors operating in China was unavailable at the time.
Most important facts for investors to verify
- Elunate sales growth, reimbursement access, pricing, and the economics and timing of HUTCHMED’s promotion and distribution rights under the amended Lilly agreement.
- Subsequent clinical results and regulatory progress, particularly FALUCA, FRUTIGA, surufatinib Phase III studies and savolitinib programs.
- Cash burn, short-term investments, facility availability, debt repayment and whether joint-venture dividends or external financing are needed to sustain development plans.
- The commercial and accounting effects of the two-invoice reform, including whether lower reported sales translate into changes in underlying profitability or cash generation.
- Resolution of Nutrition Science Partners’ impaired program and any buyer or partner outcome; also assess concentration in key commercial joint ventures and product suppliers.